Monoacylglycerol Lipase (MGLL) Polymorphism rs604300 Interacts With Childhood Adversity to Predict Cannabis Dependence Symptoms and Amygdala Habituation: Evidence From an Endocannabinoid System-Level Analysis

Grants

Funding Acknowledgements

CEC is supported by National Science Foundation predoctoral Grant DGE-1143954. AA acknowledges support from R01DA23668 and K02DA32573. TW, BZ, and DL are supported by American Cancer Society Grant RSG-14-049-01-DMC, NIH Grants R01HG007354, R01HG007175, and R01ES024992. LD is supported by an Australian National Health and Medical Research Council (NHMRC) research fellowship (1041472). ARH. receives support through National Institute on Drug Abuse Grants DA033369 and DA031579. RB receives support from the Klingenstein Third Generation Foundation and the National Institutes of Health (NIA R01-AG045231). Funding support for the Comorbidity and Trauma Study (CATS) was provided by the National Institute on Drug Abuse (R01 DA17305); GWAS genotyping services at the Center for Inherited Disease Research (CIDR) at The Johns Hopkins University were supported by the National Institutes of Health [contract N01-HG-65403]. The National Drug and Alcohol Research Centre at the University of New South Wales is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grants Fund. Funding support for the Study of Addiction: Genetics and Environment (SAGE) was provided through the NIH Genes, Environment and Health Initiative [GEI] (U01 HG004422). SAGE is one of the genome-wide association studies funded as part of the Gene Environment Association Studies (GENEVA) under GEI. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the GENEVA Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information. Support for collection of datasets and samples was provided by the Collaborative Study on the Genetics of Alcoholism (COGA; U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence (COGEND; P01 CA089392), and the Family Study of Cocaine Dependence (FSCD; R01 DA013423, R01 DA019963). Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research, was provided by the NIH GEI (U01HG004438), the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, and the NIH contract "High throughput genotyping for studying the genetic contributions to human disease"(HHSN268200782096C). The Duke Neurogenetics Study is supported by Duke University and National Institute on Drug Abuse Grant DA033369. Disclosure of interest: LJB is listed as an inventor on Issued U.S. Patent 8,080,371,"Markers for Addiction" covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. EDC is employed by 23andMe.